Background-Successful arrhythmia ablation normalizes ejection fraction (EF) in tachycardia-mediated cardiomyopathy, but recurrent heart failure and late sudden death have been reported. The aim of this study was to characterize the left ventricle (LV) of tachycardia-mediated cardiomyopathy patients long after definitive arrhythmia cure. Methods and Results-Thirty-three patients with a history of successfully ablated incessant focal atrial tachycardia 64±36 months prior, and 20 healthy controls were recruited. At ablation, 18 patients had EF<50% (AT-low EF) that recovered within 3 months from 37±12 to 56±4% (P<0.001), whereas 15 patients had EF>55% (AT-normal EF). No subjects had EF of 50% to 55%. Subjects underwent echocardiography with speckle tracking and contrast-enhanced cardiac MRI with ventricular T 1 mapping as an index of diffuse fibrosis. Contrast-enhanced cardiac MRI was performed using a clinical 1.5-T scanner and 0.2 mmol/kg gadolinium-diethylene triamine penta-acetic acid for contrast. 
T achycardia-mediated cardiomyopathy (TMC) is an important cause of reversible left ventricular (LV) systolic dysfunction and may complicate supraventricular tachyarrhythmias. 1, 2 Key features include reduced global contractility, extracellular matrix remodeling, and LV chamber dilatation. Severity of systolic impairment in TMC shows dependence on tachycardia rate and duration. [3] [4] [5] Successful rate or rhythm control results in normalization of ejection fraction (EF) within weeks to months in the absence of concurrent causes of cardiomyopathy. 1, [6] [7] [8] 
Clinical Perspective on p 704
Despite good early outcomes, rapid deterioration of systolic function with tachycardia recurrence and late sudden death have been reported, raising the possibility that LV myocardial substrate remains diseased despite normalization of overall systolic function. 8, 9 Large animal models of tachypacing-induced heart failure not only show EF recovery after cessation of tachypacing, but also reveal persistent LV dilatation accompanied by diffuse interstitial fibrosis, reduced contractility, and impaired relaxation during the immediate recovery phase. [10] [11] [12] [13] Furthermore, a series of 24 TMC patients treated successfully for a variety of arrhythmias demonstrated persistent LV dilatation ≤14 months after normalization of EF. 6 Long-term follow-up studies of TMC that characterize LV structure and function are lacking, despite increasing availability of powerful imaging modalities such as cardiac magnetic resonance (CMR). The long-term impact of incessant inappropriate tachycardia in subjects who do not develop gross LV systolic dysfunction is unknown. In this study, we performed detailed noninvasive assessment of LV function, morphology, and fibrosis, as well as clinical outcomes in a cohort of patients with and without TMC in the setting of incessant focal atrial tachycardia at a mean of 5 years after successful arrhythmia ablation.
Methods

Study Population
The study was performed at the Royal Melbourne Hospital and the Alfred Hospital in Melbourne, Australia, and had Human Research Ethics Committee approval. Consenting patients with a history of incessant focal atrial tachycardia (AT) and successful ablation between January 1997 and December 2011 were recruited. Patients with preexisting LV dysfunction were excluded. Patients were considered to have preexisting LV dysfunction when cardiomyopathy occurred in the context of known significant coronary artery disease, valvular heart disease, congenital heart disease, or inherited cardiomyopathy; cardiomyopathy had been documented before the onset of tachycardia; or the echocardiographic abnormalities were segmental or of a pattern attributable to another cause. At the time of their ablation procedure, 18 patients had an EF of ≤50% (AT-low EF), whereas 15 patients had an EF of ≥55% (AT-normal EF), as determined by Simpson's biplane method on clinical echocardiography. No patients had an EF of 50% to 55%. All 33 patients had incessant AT where tachycardia was defined by the presence of ≥10 consecutive tachycardia beats on 12-lead ECG or Holter monitor and incessant tachycardia was defined as continuous tachycardia or continuous paroxysms of tachycardia separated by ≤2 sinus beats.
14 After successful ablation, EF of all AT-low EF patients (as determined on clinical echocardiography) either recovered to >55% or made an absolute improvement of ≥10% within 3 months, resulting in a clinical diagnosis of TMC. Success of ablation was based on the absence of recurrence on symptoms and repeated electrocardiographic evaluation at 1-, 3-, 6-, and 12-month follow-up visits and annually thereafter. Holter monitoring was performed at 3-, 6-, and 12-month visits and, thereafter, if patients described symptoms. Angiotensin-converting enzymeinhibitor and β-blocker therapy was not routinely prescribed after catheter ablation. A control group comprising healthy volunteers having a similar age and sex distribution to the AT patients was recruited from the general public through advertising within our institutions. All subjects underwent clinical assessment, CMR, echocardiography, and the SF-36 Health Survey as an assessment of quality of life. 15 All prospective imaging acquisitions and analyses were performed blinded to patient study group.
CMR Protocol
Subjects underwent CMR using a clinical 1.5-T MRI scanner (Signa HD 1.5-T, GE Healthcare, WI). Sequences were acquired during breath-holds of 10 to 15 seconds. Initial cine CMR sequences were performed in 3 standard long-axis (4-, 3-, and 2-chamber views) and short-axis slices (basal, mid, and apical), kept identical for each subsequent sequence throughout the CMR examination. 16 From an end-diastolic, 4-chamber, long-axis view, 5 equally spaced short-axis slices were planned, so that the 2 outer slices lined up exactly either with the tip of the apex or the mitral annulus. The 2 outer slices were then deleted, leaving 3 slices corresponding to typical basal, mid, and apical short-axis views. To calculate LV volume and function, a contiguous short-axis steady state free precession stack was acquired (8-mm slice thickness, no gap), extending from the mitral valve annulus to the LV apex.
Delayed hyperenhancement was obtained 10 minutes after a bolus (0.2 mmol/kg bodyweight to a maximum of 20 mmol) of gadolinium-diethylene triamine penta-acetic acid (Magnevist, Schering, Germany) to identify regional fibrosis using a T 1 -weighted inversionrecovery gradient echo technique (repetition time, 7.1 ms; echo time, 3.1 ms; inversion time individually determined to null the myocardial signal; range, 180-250 ms; slice thickness, 8 mm; matrix, 256×192; number of acquisitions, 2). Delayed enhancement imaging was performed using both standard long-and short-axis views of the LV, including a contiguous stack of slices from the mitral valve annulus to the apex. For T 1 mapping, all 3 standard short-axis levels were used, commencing with the basal level and progressing apically.
For evaluation of diffuse interstitial fibrosis, a T 1 mapping sequence described previously 17 was used to acquire images over a range of inversion times. This consisted of an ECG-triggered, inversion-recovery prepared, 2-dimensional fast-gradient echo sequence using variable temporal sampling of k-space (Global Applied Science Laboratory, GE Healthcare). 18 Ten images were acquired sequentially at increasing inversion times (75-750 ms) 15 minutes postcontrast over a series of 3 to 4 breath-holds using the after imaging parameters -repetition/ echo time, 3.7 ms/1.2 ms; flip angle, 20°; 256×128 acquisition matrix; field-of-view, 36×27 cm; slice thickness, 8 mm; trigger delay, 300 ms; and views per segment, 24. Images were processed using a curve-fitting technique to generate myocardial postcontrast T 1 times as described below.
Evaluation of LV Function and Regional Fibrosis
Volumetric analysis of the LV from which EF was derived was performed using the summation of discs method. Left atrial volume was determined using the area-length method. Regional fibrosis was identified by LGE within the myocardium, defined quantitatively by a myocardial postcontrast signal intensity 5 SDs above that within a reference region of remote nonscarred myocardium within the same slice. Myocardial delayed enhancement was considered to be present only if it was identified in 2 orthogonal views.
Evaluation of Diffuse Fibrosis With T 1 Mapping
After image acquisition, the 10 short-axis images of varying inversion times were analyzed using a dedicated research software package (VizPack Version 7.2.0, Global Applied Science Laboratory, GE Healthcare). The software-enabled analysis of regions of interest to determine pixel-by-pixel and mean T 1 time by fitting data acquired at various preparation times to the exponential curve
) relating the sample magnetization M z observed at time t=TI to the equilibrium magnetization M 0 and sample T 1 , where TI denotes inversion time for an inversion-recovery experiment. For each short-axis image, an regions of interest was drawn around the entire LV myocardium (excluding papillary muscles) to determine postcontrast myocardial T 1 time. In addition, postcontrast T 1 time was determined for the LV blood pool to serve as an internal control using regions of interests traced within the LV endocardial border. This process was repeated to obtain myocardial and blood pool T 1 times at all 3 standard short-axis levels. Postcontrast T 1 time is known to be dependent on several factors including time postgadolinium infusion and renal function. 19, 20 Because postcontrast timing of image acquisitions was progressively greater from the basal to the apical slices for each patient, a correction was applied to raw T 1 time results individually and according to modeling proposed by Gai et al 20 and to yield corrected T 1 time indexed for a postcontrast time of 15 minutes and an estimated glomerular filtration rate of 90 mL/min. For each subject, a single global corrected T 1 time was calculated by averaging the corrected T 1 times at each of the 3 short-axis slices.
Echocardiography
Two-dimensional echocardiography was performed on the same day as CMR using a clinical system (Vivid 7, General Electric Vingmed, Milwaukee, WI). Images were acquired using a 3.5-MHz transducer in the standard parasternal and apical views with patients in the left lateral decubitus position. Standard M-mode and 2D images including color Doppler data for 3 consecutive heartbeats were saved in cine loop format. Analyses were performed off-line using commercially available software (Echopac 6.1, General Electric Vingmed).
Diastolic function was assessed using the mitral inflow pattern from pulsed-wave Doppler images and tissue Doppler imaging. Early (E) and late (A) diastolic filling velocities, E/A ratio, E wave deceleration time, septal and lateral early diastolic mitral annular motion velocity (e`), and the E/e` ratio were assessed. The anteroposterior diameter of the left atrium was measured at end-systole on the M-mode image obtained from the parasternal long-axis view.
Strain Analysis
LV deformation was assessed using 2D speckle tracking strain imaging. Deformation of the LV was determined in 3 directions: (1) radial strain, reflecting myocardial thickening/thinning in the shortaxis plane; (2) circumferential strain, reflecting myocardial shortening/lengthening in the short-axis plane; and (3) longitudinal strain, reflecting myocardial shortening/lengthening in the long-axis plane. Peak systolic radial and circumferential strain and strain rate were calculated by averaging the peak systolic values of 18 segments, derived from the 6 segments of the 3 short-axis views (basal, mid, and apical LV). Peak systolic longitudinal strain and strain rate were calculated by averaging the peak systolic values of 18 segments, derived from the 6 segments of the 3 apical views (apical long axis and 2-and 4-chamber views). Early diastolic strain rate was calculated by averaging the values at the time of peak E for 18 segments, derived from the 6 segments of the 3 apical views. Cardiac rotation curves as mean curves of all 6 segments were derived from basal and apical LV short-axis views. Twist and twist rate curves were generated based on the difference between apical and basal rotation curves. Clockwise rotation was marked as a positive value (twist) and counterclockwise rotation as a negative value (untwist).
Statistics
All data are expressed as mean±SD unless otherwise indicated. Comparisons between 2 groups were made using Student t test for continuous variables and Fisher Exact test for categorical variables. For comparisons across 3 groups, 1-way analysis of variance (ANOVA) with Bonferroni correction was used for approximately normally distributed variables and Kruskal-Wallis test with Bonferroni correction for non-normally distributed variables. Simple and multiple linear regressions were used to assess predictors of postcontrast ventricular T 1 time. A P value of <0.05 was considered significant, and all reported P values are 2-tailed. Analyses were conducted using SPSS software (version 17, SPSS, Chicago, IL).
Results
Subject Characteristics
Thirty-three patients with a history of successful ablation for incessant atrial tachycardia were recruited (Table 1) : 18 with a history of TMC (AT-low EF) and 15 without (AT-normal EF). AT-low EF and AT-normal EF patients were recruited 56±41 and 75±28 months after successful ablation (P=ns). Two ATlow EF patients each had 1 previous attempt at ablation that was unsuccessful before the successful ablation procedure. There were no differences in mean preablation heart rate on 24-h holter monitoring, AT symptom duration, or AT cycle length between the 2 AT patient groups (P=ns). AT-normal EF patients had an index EF of 60±7% and did not have routine follow-up echocardiography. AT-low EF patients had an index EF of 36±12%, which was significantly lower than ATnormal EF patients (P<0.0001; unpaired t test), and recovered to 56±4% by 3 months postablation (P<0.0001; paired t test). A further 20 healthy control subjects were recruited for this study. Healthy controls, AT-normal EF patients, and AT-low EF patients had a similar age and sex distribution. At follow-up, patients were generally free of comorbidities. Three AT-low EF patients were prescribed both angiotensin-converting enzyme-inhibitor and β-blocker therapy: 2 had developed concomitant hypertension and coronary artery disease after index presentation and 1 remained on the combination from the time of diagnosis of TMC. Of AT-normal EF patients, 2 were prescribed angiotensin-converting enzyme-inhibitor therapy only for diabetes and hypertension.
CMR Findings
Results are detailed in Table 2 . Of the 18 AT-low EF patients, 2 had received implantable cardioverter-defibrillators for primary prophylaxis before successful ablation of atrial tachycardia, precluding CMR. Both devices were left in situ after normalization of EF and at follow-up had never recorded ventricular arrhythmia. Remaining AT-low EF patients had larger indexed LV end-diastolic volume, larger indexed end-systolic volume, and lower LV EF compared with healthy controls and AT-normal EF patients. No subject had delayed regional myocardial enhancement.
The time delay from gadolinium infusion to image acquisition increased overall across the 3 short-axis planes from 22.6±2.9 minutes (basal LV) to 27.0±3.7 minutes (mid LV) and 31.4±4.6 minutes (apical LV; P<0.001). However, the time delay from gadolinium infusion to image acquisition was not significantly different between the 3 groups at each of the 3 LV short-axis planes (P=ns for all comparisons). After correction of T 1 time for postcontrast time delay and estimated glomerular filtration rate, there were no significant differences in postcontrast T 1 time between the 3 LV short-axis planes within each of the 3 groups (P=ns for all comparisons). Global corrected T 1 time was shorter in AT-low EF patients compared with controls (442±53 versus 506±61 ms; P<0.05). This difference remained significant after exclusion of apical T 1 time measurements, a potential source of error because of their smaller size and the influence of noise and patient specific delays (440±54 versus 492±70; P<0.05).
Predictors of Ventricular T 1 Time in AT-Low EF Patients
Simple and multiple linear regressions were performed to assess predictors of fibrosis as measured by ventricular T 1 time, using the following known and putative predictors of diffuse fibrosis: age, mean heart rate on 24-h holter monitoring, AT symptom duration, index EF, and postablation follow-up duration (Table 3 
Echocardiographic Findings
There were no significant differences in diastolic parameters across the 3 groups (Table 4) . Speckle tracking analysis revealed subtle differences in LV systolic and diastolic function (Table 5 ). Despite having recovered EF within the normal range, AT-low EF patients showed attenuated global circumferential strain, global longitudinal strain, and twist rate compared with healthy controls and AT-normal EF patients. Global early diastolic strain rate was also reduced compared with controls. Speckle tracking analysis showed no differences between AT-normal EF and control subjects.
Discussion
In this study, we characterized LV structure and function in patients with a past history of TMC induced by incessant focal atrial tachycardia, late after successful ablation of the culprit arrhythmia. This is a unique patient cohort as longterm arrhythmia cure is feasible. Our major findings, 5 years after successful ablation, are as follows: (1) LV indices of TMC patients were within normal ranges on CMR, echocardiography, and strain analysis; (2) TMC patients showed subtle differences in LV structure and function compared with controls, with larger LV dimensions, lower EF, and attenuated myocardial strain and twist rate; and (3) compared with controls, TMC patients had reduced global corrected T 1 time consistent with diffuse myocardial fibrosis. Clinical studies of TMC consistently document good outcomes in the early recovery phase with EF recovering to the normal range within 1 to 6 months of treatment. 6, 8, 9, 21, 22 However, late adverse outcomes have been reported. 8, 9 Among a cohort of 24 TMC patients (EF 26±9%) followed for a mean of 26 months after treatment, Nerheim et al 9 reported 5 cases of recurrent heart failure in which EF declined precipitously with recurrent tachycardia. In addition, 3 relatively young men suffered unexpected sudden cardiac death at 6 months, 9 months, and years after recovery of normal EF. However, all 3 had recurrent and persistent atrial fibrillation before death and 1 had undergone atrioventricular node ablation and pacing. Thus, none of the 3 had been cured of the index arrhythmia and the cause of death was uncertain. Nevertheless, these 3 patients had significantly depressed index EF compared with the rest of the cohort (16±5%). Watanabe et al 8 reported similar findings among 12 TMC patients (EF, 32±10%; New York Heart Association Heart functional class, 2.3±0.5): 2 patients experienced rapid return of systolic dysfunction with tachycardia recurrence, and 1 patient died suddenly 40 months after EF recovery in the absence of documented recurrent tachycardia and heart failure. These observations suggest that persistent ultrastructural changes of the myocardium may provide an arrhythmogenic substrate and predispose to LV deterioration in the face of repeated stress. Indeed, Dandamudi et al 6 demonstrated persistent LV dilatation in 24 TMC patients ≤14 months after appropriate treatment and normalization of EF.
Our study revealed differences in LV structure and function in TMC patients compared with controls years after definitive treatment of the culprit tachycardia. Our cohort is unique in being composed of patients with TMC who were largely free of important confounding influences. All patients presented with incessant focal atrial tachycardia with minimal comorbidities, underwent curative ablation, and had no recurrence at follow-up. In contrast, the majority of patients in previous TMC series have had cardiomyopathy secondary to atrial fibrillation/flutter. [7] [8] [9] 21 In these series, outcomes may have been negatively biased by the presence of conditions associated with these arrhythmias such as preexisting hypertension and heart failure. Cases of atrial fibrillation were generally treated with pharmacological rate-control or cardioversion, allowing the confounding influence of arrhythmia recurrence and unrecognized periods of poor rate-control to bias results. Evidence of a negative impact of irregular ventricular rhythm per se on ventricular function despite controlled ventricular rate also exists. 21, 23 In contrast, focal atrial tachycardia is considered a sporadic arrhythmia not known to be influenced by preexisting ventricular cardiomyopathy. Our patients did not experience the adverse outcomes of recurrent heart failure and sudden death described in previous series. 8, 9 In 2 patients with severely depressed index EF who received implantable cardioverter-defibrillator implantation for primary prophylaxis, no ventricular arrhythmias were recorded. However, our TMC cohort had less severe systolic impairment at presentation in comparison to these previous series and this may account for differences in observed outcomes (index EF of 36±12% versus 28±10%; P<0.05).
TMC is well studied in porcine and canine tachypacing models, and is characterized by spherical LV dilatation, systolic dysfunction, elevated filling pressures, diminished AT indicates atrial tachycardia; B, standardized (beta) coefficient; and EF, ejection fraction. *Adjusted R cardiac output, reduced systemic vascular resistance, and neurohormonal activation. 24 LV dilatation is more pronounced for end-systolic than end-diastolic indices. 25, 26 Systolic dysfunction results from loss of myocardial contractility and contractile reserve reflected by whole heart and isolated cardiomyocyte indices. 10, 25 After resumption of normal sinus rhythm, EF typically shows dramatic recovery in the first 24 to 48 hours, subsequently normalizing in the following weeks. 1, 4, 26 Nevertheless, attenuation of contractile function and relaxation remain measurable at the cellular level 4 weeks after cessation of tachypacing, and LV volumes remain elevated. 10 Development of LV hypertrophy and an increase in diffuse interstitial fibrosis are also observed, and the resulting reduction in wall stress, rather than normalization of LV geometry or myocyte contractility, mediates improved pump function at this stage. [10] [11] [12] With the exception of LV hypertrophy, animal model findings in the early recovery phase bear striking resemblance to those of late follow-up in the human setting as demonstrated by our study. We made the further observation that the degree of fibrosis correlated with arrhythmia symptom duration, but not index EF, consistent with the notion that systolic dysfunction and fibrosis run independent courses during the induction and recovery phases of TMC as observed in animal models.
The exact mechanism by which fibrosis is induced in this setting remains to be clearly defined. Porcine heart failure induced by rapid atrial pacing has been associated with reduced ventricular collagen concentration, cross-linking, and fibril diameter; whereas cessation of rapid pacing resulted in recovery of systolic function accompanied by increased collagen concentration and thickened collagen weave. 11, 12 Similar findings have been replicated in dogs. 27 After induction of heart failure by rapid pacing, LV fibroblasts isolated from failing pig hearts showed increased formation of fibrillar collagen, increased adhesion to and migration through extracellular matrix substrates, and differences in fibroblast associated integrins. 28 In a canine model of tachypacing-induced heart failure, isolated ventricular fibroblasts exhibited increased proliferation rates. 29 Interestingly, phenotypic changes in TMC fibroblast biology appear to remain stable for several generations of cell culture passages. 28 Collectively, these observations point to a significant and stable transformation of fibroblast phenotype in response to cardiomyopathy induced by rapid ventricular rates, which may explain the presence and persistence of LV fibrosis noted in our patients.
Our finding of diffuse LV fibrosis many years after curative ablation is highly relevant, as this may provide a substrate for late arrhythmic events proposed to account for sudden death observed in previous series. 8, 9 Extensive evidence supports the role of fibrosis in ventricular arrhythmogenesis. 30 Among sudden death autopsy series, ventricular interstitial fibrosis in the absence of other structural abnormalities is a consistent albeit uncommon finding, affecting an estimated 1 to 3% of cases. [31] [32] [33] Murine models show a clear relationship between inducibility of ventricular arrhythmias and degree of interstitial fibrosis. 34, 35 Increased fibrosis alters tissue electrophysiology through partial decoupling of muscle fibres, conduction slowing, zigzag courses of conduction propagation, localized source-sink mismatches, and conduction blocks. [36] [37] [38] Furthermore, myofibroblast coupling to cardiomyocytes through gap junction formation imparts enhanced automaticity to cardiomyocytes when coupled to a critical number of myofibroblasts. 39 Recent complete heart studies demonstrate the role of fibrosis in modulating formation of early afterdepolarizations that lead to triggered activity causing ventricular fibrillation. 40, 41 It is well established that oxidative stress promotes early afterdepolarizations and triggered activity in isolated cardiomyocytes. 42 This same stress fails to cause early afterdepolarizations in well-coupled, nonfibrotic hearts because of source-to-sink mismatches arising from cell-to-cell coupling, but readily induces ventricular tachycardia (VT) and ventricular fibrillation in diffusely fibrotic rat and rabbit hearts. AT indicates atrial tachycardia; EF, ejection fraction; GCS(r), global circumferential strain (rate); GEDSr , global early diastolic strain rate, GLS(r), global longitudinal strain (rate); and GRS(r), global radial strain (rate). *Significant difference compared with controls. †Significant difference compared with AT-normal EF patients.
40,41
Optical mapping and roving glass microelectrode single cell action potential recordings revealed triggered activity causing focal VT that degenerates within seconds to ventricular fibrillation after the emergence of spatially discordant action potential duration alternans leading to wave break, reentry, and ventricular fibrillation. 30 Thus, the first-hit of ventricular fibrosis in this paradigm does not generate ventricular arrhythmia alone, but requires a second-hit of oxidative stress to do so.
Diffuse ventricular fibrosis in our TMC cohort may reflect an arrhythmogenic substrate that has remained asymptomatic because of absence of an appropriate trigger. Sudden deaths in previous reports potentially represent lethal ventricular arrhythmias triggered by the oxidative stress associated with tachycardia recurrence, 43, 44 or some other physiological insult. Whether patients with TMC would benefit from a period of antifibrotic or antifailure pharmacotherapy remains to be studied.
Study Limitations
Patient numbers were limited by the scarcity of cases with atrial tachycardia-induced TMC at our centers. However, our study is the first to report on a group of TMC patients receiving definitive cure for their inciting arrhythmias, and has a long follow-up duration. Retrospective study design did not allow exclusion of ventricular abnormalities before development of arrhythmia. Furthermore, lack of baseline CMR and strain imaging precluded temporal comparisons at follow-up. Although an antecedent cardiomyopathy causing incessant focal AT is a theoretical consideration, we are not aware of any previous description of such a relationship in the human literature, and the prompt resolution of systolic dysfunction after successful arrhythmia ablation points against this possibility. Nevertheless, we cannot exclude the possibility that the structural and ultrastructural changes we observed after resolution of systolic dysfunction in TMC patients were present before the development of TMC. However, this would challenge the current paradigm of TMC that affected patients have normal hearts before the development of incessant AT, suggesting that the development of TMC requires the presence of adverse cardiac remodeling plus the advent of incessant AT. Several AT patients with hypertension, diabetes, coronary disease, and longstanding ACE-inhibitor/β-blocker therapy were included in our analyses. Regardless, the key finding of shorter global corrected ventricular T 1 time in TMC patients versus controls remained significant after exclusion of these 5 patients (439±55 versus 506±61 ms; P<0.05). We did not confirm the presence of interstitial fibrosis histologically, but relied on a histologically validated contrast-enhanced T 1 mapping technique to determine its presence. Although several T 1 mapping methodologies have been described, the largest body of data in cardiomyopathy patients using human histology as a reference standard has been acquired with the postcontrast T 1 technique used in this study.
17,45
Conclusions
TMC patients exhibit subtle changes in LV structure and function including diffuse fibrosis long after arrhythmia cure and return to normal EF, indicating that recovery is incomplete.
CLINICAL PERSPECTIVE
Tachycardia-mediated cardiomyopathy is an important cause of reversible left ventricular (LV) systolic dysfunction and may complicate supraventricular tachyarrhythmias. It is characterized by impaired global contractile function, which recovers after abolition of the inciting tachyarrhythmia. Despite good early outcomes, rapid deterioration of systolic function with tachycardia recurrence and late sudden death have been reported, raising the possibility that LV myocardial substrate remains diseased despite normalization of overall systolic function. In view of such observations, this study examined LV structure and function in a cohort of tachycardia-mediated cardiomyopathy patients a mean of 5 years after ablation of incessant focal atrial tachycardia. In contrast with previous series, which have largely included patients with atrial fibrillation managed with rate or rhythm control, we studied a unique cohort comprising patients in whom curative ablation was achieved. No episodes of recurrent heart failure or ventricular arrhythmia were recorded during the follow-up period. Cardiac MRI demonstrated that global LV function and dimensions were within normal limits at late follow-up. However, postcontrast ventricular T 1 mapping revealed the presence of diffuse LV fibrosis, indicating that recovery was incomplete.
